A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation
Elena Rampazzo1, Monica Dettin2, Francesca Maule3
1Department of Woman and Children's Health, University of Padova, via Giustiniani 3, 35128 Padova, Italy; Istituto di Ricerca Pediatrica (IRP) Città della Speranza, corso Stati Uniti 4, 35127 Padova, Italy.
Background:
Glioblastoma (GBM) is the most aggressive type of primary brain tumor, characterized by the intrinsic resistance to chemotherapy due to the presence of a highly aggressive Cancer Stem Cell (CSC) sub-population. In this context, Bone Morphogenetic Proteins (BMPs) have been demonstrated to induce CSC differentiation and to sensitize GBM cells to treatments.
Methods:
The BMP-2 mimicking peptide, named GBMP1a, was synthesized on solid-phase by Fmoc chemistry. Structural characterization and prediction of receptor binding were obtained by Circular Dicroism (CD) and NRM analyses. Activation of BMP signalling was evaluated by a luciferase reporter assay and western blot. Pro-differentiating effects of GBMP1a were verified by immunostaining and neurosphere assay in primary glioblastoma cultures.
Results:
CD and NMR showed that GBMP1a correctly folds into expected tridimensional structures and predicted its binding to BMPR-IA to the same epitope as in the native complex. Reporter analysis disclosed that GBMP1a is able to activate BMP signalling in GBM cells. Moreover, BMP-signalling activation was specifically dependent on smad1/5/8 phosphorylation. Finally, we confirmed that GBMP1a treatment is sufficient to enhance osteogenic differentiation of Mesenchymal Stem Cells and to induce astroglial differentiation of glioma stem cells (GSCs) in vitro.
Conclusions:
GBMP1a was demonstrated to be a good inducer of GSC differentiation, thus being considered a potential anti-cancer tool to be further developed for GBM treatment.
General Significance:
These data highlight the role of BMP-mimicking peptides as potential anti-cancer agents against GBM and stimulate the further development of GBMP1a-based structures in order to enhance its stability and activity.
Insights
A novel peptide, GBMP1a, mimics Bone Morphogenetic Proteins (BMPs) to induce differentiation in glioblastoma stem cells (GSCs). This peptide shows potential as an anti-cancer agent for treating aggressive brain tumors like glioblastoma.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor known for chemotherapy resistance due to cancer stem cells (CSCs).
- Bone Morphogenetic Proteins (BMPs) can induce CSC differentiation and sensitize GBM cells to therapy.
Purpose of the Study:
- To synthesize and characterize a BMP-2 mimicking peptide, GBMP1a.
- To evaluate the efficacy of GBMP1a in inducing differentiation of glioma stem cells (GSCs) and activating BMP signaling.
Main Methods:
- Solid-phase peptide synthesis using Fmoc chemistry.
- Structural analysis via Circular Dicroism (CD) and Nuclear Magnetic Resonance (NMR).
- BMP signaling activation assessed by luciferase reporter assays, Western blot, and in vitro differentiation assays.
Main Results:
- GBMP1a adopts correct 3D structures and binds to BMPR-IA.
- GBMP1a activates BMP signaling in GBM cells, dependent on smad1/5/8 phosphorylation.
- GBMP1a induces osteogenic differentiation in Mesenchymal Stem Cells and astroglial differentiation in GSCs.
Conclusions:
- GBMP1a effectively induces GSC differentiation, presenting a potential therapeutic strategy for GBM.
- BMP-mimicking peptides are promising anti-cancer agents for GBM, warranting further development of GBMP1a for enhanced stability and activity.
More Related Videos
09:18Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018